Medpace (NASDAQ:MEDP) Releases Quarterly Earnings Results, Beats Expectations By $0.54 EPS

Medpace (NASDAQ:MEDP) issued its quarterly earnings results on Wednesday. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54, FiscalAI reports. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million.

Medpace Stock Performance

Medpace stock traded down $6.44 during mid-day trading on Wednesday, reaching $508.46. The company’s stock had a trading volume of 385,594 shares, compared to its average volume of 342,794. Medpace has a 12-month low of $282.84 and a 12-month high of $628.92. The company has a market capitalization of $14.52 billion, a P/E ratio of 33.23, a PEG ratio of 2.49 and a beta of 1.39. The firm’s fifty day moving average price is $469.72 and its two-hundred day moving average price is $537.76.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Zacks highlights Medpace’s growth attributes — strong revenue and earnings growth, high ROE, and long-term pipeline potential — arguing MEDP remains a solid growth stock that could deliver exceptional returns if execution continues. Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think “Yes”
• Neutral Sentiment: Cincinnati plans a bike path near Medpace’s Madisonville headquarters — a local infrastructure project with limited direct financial impact but positive for community relations and employee access. Cincinnati to build bike path near headquarters of one of region’s largest companies
• Neutral Sentiment: Market previews and analyst notes ahead of Medpace’s Q1 report could drive volatility around the print; investors should watch guidance commentary vs. expectations. Medpace (MEDP) Q1 Earnings: What To Expect
• Negative Sentiment: Multiple law firms have filed claims or are soliciting lead plaintiffs in a securities class action alleging Medpace overstated growth projections and harmed investors (class period: April 22, 2025 — February 9, 2026). Firms are urging investors to seek lead?plaintiff status before a June 8, 2026 deadline — the surge of notices increases legal overhang and headline risk that likely pressured the stock. Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Geneos Wealth Management Inc. boosted its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Quarry LP bought a new position in Medpace in the 3rd quarter valued at $35,000. Greenline Wealth Management LLC bought a new position in Medpace in the 4th quarter valued at $55,000. Group One Trading LLC boosted its holdings in Medpace by 120.0% in the 4th quarter. Group One Trading LLC now owns 100 shares of the company’s stock valued at $56,000 after purchasing an additional 600 shares during the period. Finally, Johnson Financial Group Inc. boosted its holdings in Medpace by 115.7% in the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock valued at $57,000 after purchasing an additional 59 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MEDP. Royal Bank Of Canada began coverage on shares of Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Weiss Ratings lowered shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a research note on Friday, February 13th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.